In this article, we will discuss Ramucirumab (14). So, let’s get started.
An increased incidence of severe hypertension occurred in patients receiving Ramucirumab as a single agent (8%) as compared to placebo (3%) and in patients receiving Ramucirumab plus paclitaxel (15%) as compared to placebo plus paclitaxel (3%).
Control hypertension prior to initiating treatment with Ramucirumab. Monitor blood pressure every two weeks or more frequently as indicated during treatment.
Temporarily suspend Ramucirumab for severe hypertension until medically controlled. Permanently discontinue Ramucirumab if medically significant hypertension cannot be controlled with antihypertensive therapy or in patients with hypertensive crisis or hypertensive encephalopathy.